Genmab A/S (GMAB) released updated results from cohort B2 of its Phase 1/2 RAINFOL-01 clinical trial, evaluating rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC) targeting folate receptor alpha (FRa) and delivering a TOPO1 inhibitor payload. The data, presented at the European Society for Medical Oncology (ESMO) Congress in Berlin, highlight promising efficacy in heavily pretreated patients with advanced endometrial cancer (EC).
At a median follow-up of one year, patients receiving Rina-S at 100 mg/m² every three weeks (Q3W) achieved a confirmed objective response rate (ORR) of 50.0%, including two complete responses (CR). Notably, 63.6% of responders—including those with CRs—maintained their responses and remained on treatment at the one-year mark. These clinical benefits were observed regardless of FRa expression levels, suggesting broad potential for Rina-S across diverse patient profiles.
Genmab continues to evaluate Rina-S as a single agent in advanced EC through its ongoing Phase 2 RAINFOL-01 and Phase 3 RAINFOL-03 trials.
In recognition of its potential, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Rina-S for the treatment of adult patients with recurrent or progressive EC who have progressed following prior platinum-based chemotherapy and PD-(L)1 therapy.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.